# US 2020/0369766 A1 · LAG3 Binding Peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369766 A1
- Document ID: US20200369766A1
- Status: Published application
- Kind: A1
- Application number: 16/879,884
- Filed: 2020-05-21
- Published: 2020-11-26
- Earliest claimed: 2019-05-22
- Assignees: Leidos, Inc.
- Applicants: Leidos, Inc.
- Inventors: Gabriel M. Gutierrez; Vinayaka Kotraiah; Timothy W. Phares; James Pannucci; Marc Mansour
- Web page: https://patentgrep.com/patent/US20200369766A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 2039/55516: {Proteins; Peptides}
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

## Claims

### Claim 1

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1, 2, 3, 4, 5, 6, and 7.

### Claim 2 (depends on 1)

The peptide of claim 1, which consists essentially of the amino acid sequence.

### Claim 3 (depends on 2)

The peptide of claim 2, which consists of the amino acid sequence.

### Claim 4 (depends on 1)

A nucleic acid encoding the peptide of claim 1.

### Claim 5 (depends on 4)

The nucleic acid of claim 4, which is an expression construct.

### Claim 6 (depends on 5)

The nucleic acid of claim 5, which is present in a CAR-T cell or an oncolytic virus.

### Claim 7 (depends on 4)

The nucleic acid of claim 4, wherein the nucleic acid is selected from the group consisting of DNA, cDNA, PNA, and RNA.

### Claim 8 (depends on 4)

A host cell comprising the nucleic acid of claim 4.

### Claim 9 (depends on 1)

A peptide composition consisting essentially of one or more peptides of claim 1.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising:
(a) an active agent selected from the group consisting of:
(i) a peptide of claim 1;
(ii) a nucleic acid encoding the peptide;
(iii) a CAR-T cell expressing the peptide; and
(iv) an oncolytic virus expressing the peptide; and
(b) a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the active agent is the nucleic acid, wherein the nucleic acid is selected from the group consisting of DNA, cDNA, PNA, and RNA.

### Claim 12 (depends on 10)

The pharmaceutical composition of claim 10, wherein the nucleic acid is RNA.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the RNA comprises a modification selected from the group consisting of (i) modification of a ribose sugar, (ii) modification of a phosphate linkage, and (iii) modification of a base.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the modification is selected from the group consisting of a ribo-difluorotoluyl nucleotide, a 4′-thio modified RNA, a boranophosphate linkage, a phosphorothioate linkage, a 2′-O-methyl (2′-OMe) sugar substitution, a 2′-fluoro (2′-F), a 2′-O-methoxyethyl (2′-MOE) sugar substitution, a locked nucleic acid (LNA), and an L-RNA.

### Claim 15 (depends on 10)

The pharmaceutical composition of claim 10, wherein the active agent is the peptide, wherein the peptide is provided with a peptide carrier system selected from the group consisting of a microparticle, a polymeric nanoparticle, a liposome, a solid lipid nanoparticle, a hydrophilic mucoadhesive polymer, a thiolated polymer, a polymer matrix, a nanoemulsion, and a hydrogel.

### Claim 16 (depends on 10)

A method of inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, or enhancing a response to a vaccine, comprising administering to an individual in need thereof an effective amount of the pharmaceutical composition of claim 10.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is administered to inhibit progression of the hyperproliferative disorder.

### Claim 18 (depends on 17)

The method of claim 17, wherein the hyperproliferative disorder is a cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer is a melanoma.

### Claim 20 (depends on 19)

The method of claim 19, wherein the second therapy is selected from the group consisting of:
(i) a cancer vaccine;
(ii) a chimeric antigen receptor (CAR) T cell therapy;
(iii) a therapy that comprises reducing or blocking activity of a molecule selected from the group consisting of PD-1, PD-L1, lymphocyte-activation gene-3 (LAG3), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), V-domain Immunoglobulin Suppressor of T cell Activation (VISTA), T-cell Immunoglobulin domain and Mucin domain 3 (TIM-3), a killer immunoglobulin-like receptor (KIR), indoleamine (2,3)-dioxygenase (IDO), B and T Lymphocyte Attenuator (BTLA), A2A adenosine receptor (A2AR);
(iv) a cytokine;
(v) an agonist of a molecule selected from the group consisting of CD40, OX40, glucocorticoid-induced tumor necrosis factor-related protein (GITR), and Inducible T-cell COStimulator (ICOS);
(vi) an oncolytic virus; and
(vii) a therapeutic agent selected from the group consisting of a 4-1BB agonist, a 4-1BB antagonist, an inhibitor of anaplastic lymphoma kinase (ALK),
an inhibitor of histone deacetylase (HDAC), and an inhibitor of VEGFR.

### Claim 21 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is administered to inhibit the progression of a synucleinopathy.

### Claim 22 (depends on 21)

The method of claim 21, wherein the synucleinopathy is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA).

### Claim 23 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is administered to inhibit the progression of sepsis.

### Claim 24 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is administered to inhibit the progression of an infectious disease.

### Claim 25 (depends on 16)

The method of claim 16, wherein the pharmaceutical composition is administered to enhance a response to a vaccine.
